Over the past two decades, regenerative medicine has rapidly evolved from experimental science into a clinically applicable field offering new therapeutic options for patients with chronic, degenerative, autoimmune, and neurological diseases. Stem cell treatment abroad has become a strategic choice for patients seeking advanced, personalized, and multidisciplinary approaches that may not yet be widely available in their home countries.
International stem cell clinics provide access to broader cell sources, specialized laboratories, cryobanks, translational research departments, and integrated long-term medical supervision. For many patients, treatment abroad is not only about therapy itself, but about receiving care within a scientifically driven ecosystem where clinical practice, research, and innovation are closely interconnected.
Our international stem cell treatment network represents exactly this model.
Our International Presence: Clinics and Official Offices
We operate through two legal official international offices and clinical locations, strategically positioned in Ukraine and Bulgaria, each functioning as a fully independent regenerative medicine center.
Ukraine ( Kyiv): A Large Multidisciplinary Medical and Research Hub
Our Ukrainian location is based within a large hospital complex, allowing close collaboration with multiple university clinics, academic institutions, and specialized medical departments. This infrastructure provides access to a wide spectrum of clinical expertise, diagnostic capabilities, and translational research opportunities.
Key features of our Ukrainian center include:
- A fully equipped stem cell clinic
- A licensed cryobank
- An advanced cell processing laboratory
- A dedicated Research and Protocol Development Department
The Ukrainian center plays a central role in scientific research, clinical protocol development, and long-term outcome analysis, making it a cornerstone of our entire international network.
Bulgaria( Sofia): A European Clinical and Cryopreservation Center
Our Bulgarian office and clinic serve as an important European gateway for patients from the EU, Middle East, and other regions. This location integrates:
- A modern regenerative medicine clinic
- A cryobank compliant with European standards
- A laboratory specializing in cell preparation, storage, and distribution
The Bulgarian center focuses on clinical application, patient coordination, and follow-up care, working closely with the Ukrainian research division to implement individualized protocols.
Integrated Infrastructure: Clinics, Cryobanks, and Laboratories
One of the defining strengths of our organization is the full vertical integration of regenerative medicine services.
Clinical Facilities
Each clinical location is designed to provide:
- Advanced diagnostics
- Inpatient and outpatient regenerative procedures
- Multidisciplinary medical consultations
- Continuous monitoring during and after therapy
Cryobanking Capabilities
Our cryobanks ensure:
- Long-term storage of autologous and donor-derived cells
- Strict temperature control and quality assurance
- Traceability and safety at every stage of cell handling
- Availability of cells for repeat or staged therapies
Cell Processing Laboratories
Our laboratories perform:
- Isolation and expansion of stem cells
- Differentiation into specialized cell types
- Quality control, sterility testing, and viability assessment
- Preparation of intracellular and extracellular biologic products
This integrated model allows full control over the therapeutic process—from cell sourcing to patient follow-up.
Research and Protocol Development Department (Ukraine)
A unique feature of our organization is the Research and Protocol Development Department, located in Ukraine due to the size of the hospital and its collaboration with university medical centers.
Role of the Research Department
The department is responsible for:
- Analyzing clinical outcomes
- Developing disease-specific treatment protocols
- Optimizing cell combinations and dosages
- Studying long-term safety and efficacy
- Integrating new scientific findings into clinical practice
Collaboration with Universities and Clinics
Through partnerships with university hospitals, the department participates in:
- Translational research projects
- Clinical observations and registries
- Comparative analysis of different cell types
- Development of personalized regenerative strategies
This academic integration ensures that our protocols are data-driven, continuously evolving, and clinically grounded.
Scientific and Clinical Leadership in Stem Cell Therapy: Ukraine and Bulgaria
Ukraine has played a pioneering role in the development of stem cell science and regenerative medicine in Eastern Europe and globally. Fundamental research involving multiple types of stem and progenitor cells has been conducted at the academic and scientific level in Ukraine since 1985, long before cell therapy entered widespread clinical discussion in many countries. This early scientific foundation enabled the country to establish a structured and legally regulated framework for translational and clinical applications of cellular technologies.
Read more about stem cells therapy:Is Stem Cell Therapy Safe?
A major milestone was achieved in 1999, when the Parliament of Ukraine adopted the Law of Ukraine on the Transplantation of Organs and Other Anatomical Materials to Humans. This legislation formally regulated the medical use of fetal-derived, umbilical, and other stem cell types for the treatment of severe and life-threatening conditions. Importantly, the law defined the introduction of stem cells into the human body as a form of transplantation, with the cells themselves classified as biological grafts. Since the adoption of this framework, dozens of preclinical studies and clinical trials have been conducted to evaluate the safety, feasibility, and therapeutic potential of stem cell transplantation across a wide range of indications.
Building on this long-standing regulatory and scientific background, our organization has become one of the recognized pioneers in cell therapy, with more than 37 years of continuous experience in the development and clinical application of cryopreserved, tissue-specific stem and progenitor cells of various origins. Our expertise spans the entire lifecycle of cellular products—from tissue procurement and cell isolation to cryopreservation, quality control, and clinical delivery.
Largest Cell Banking Infrastructure and Global Clinical Collaboration
We operate one of the largest and most advanced cell banking infrastructures in Ukraine, with parallel clinical and biotechnological facilities in Bulgaria, allowing us to serve patients across Europe, the Middle East, Asia, and North America. Our biobanking and cell distribution programs have successfully provided biological materials and individualized cellular therapies to patients from Poland, Israel, the United States, China, the United Arab Emirates, Turkey, Germany, and other countries.
Our work is conducted within the framework of international medical and scientific collaboration. On a legal and institutional basis, we cooperate with leading global medical centers, including Charité – Universitätsmedizin Berlin, Sheba Medical Center (Israel), Munich University Hospital, and Mayo Clinic (USA). These collaborations support knowledge exchange, protocol development, and alignment with international clinical standards.
Regulatory Compliance Across Jurisdictions
Stem cell banking and clinical application are regulated differently across countries, and our operations are designed to comply with both national and international regulatory requirements.
In the United States, umbilical cord blood banking is strictly supervised by the Food and Drug Administration (FDA), which also regulates the clinical use of certain stem cell products for specific indications. Additionally, states such as New York, New Jersey, and California require specialized accreditation for cord blood banks; without such accreditation, a biobank is not legally permitted to operate.
Within the European Union, cord blood and tissue banks are coordinated and supervised through international regulatory frameworks, including NetCord, an organization supported by the European Parliament. NetCord oversees compliance, quality standards, and ethical practices while also promoting public awareness of umbilical cord blood banking.
In Ukraine and Bulgaria, stem cell and tissue banking activities are regulated through licensing systems established by the Ministries of Health, requiring strict adherence to defined technical, medical, and ethical standards. Only facilities that meet these requirements are authorized to perform cell and tissue preservation, processing, and clinical use.
Patented Technologies and Peer-Reviewed Scientific Output
All of our core technologies are patented and protected by intellectual property rights. Our scientific developments and clinical findings are actively published in respected national and international peer-reviewed journals, including Cell Biology and Translational Medicine, MDPI journals, Oxford University Press publications, World Journal of Stem Cells, Life Sciences, and other authoritative scientific outlets.
This publication activity reflects our commitment to transparency, reproducibility, and integration into the global scientific community.
National and International Scientific Expertise
Our consulting and advisory board includes leading experts from the Ministry of Health and the National Academy of Sciences of Ukraine, as well as senior researchers and clinicians from specialized research institutes. Through partnerships with major Ukrainian and Bulgarian research centers, we actively contribute to the advancement of regenerative medicine, translational research, and evidence-based clinical protocols.
Membership in International Scientific Societies
We are proud members of key international professional organizations, including:
- International Society for Cell & Gene Therapy (ISCT)
- International Placenta Stem Cell Society (IPLASS)
- International Society for Stem Cell Research (ISSCR)
- International Federation of Placental Research Associations (IFPA)
These memberships ensure ongoing alignment with global scientific standards, ethical guidelines, and emerging best practices.
Certified Quality Management and Operational Excellence
Our operations are governed by the ISO 9001:2015 international quality management system, which enables continuous monitoring and optimization of both medical services and technological processes. Independent audits confirming compliance with ISO standards have been conducted by TÜV Rheinland / LGA InterCert (Germany), one of the world’s leading certification bodies.
OUR SUCCESS RATES IN STEM CELLS THERAPY: Stem Cell Therapy Success Rate: What Patients Should Know About Effectiveness and Results
Broad Spectrum of Stem Cell Types and Advanced Differentiation Potential
Our clinics operate across the full spectrum of modern cellular and regenerative medicine, working with virtually all clinically relevant types of cells and cellular materials. These include autologous and allogeneic stem and progenitor cells derived from umbilical cord blood, umbilical cord tissue (Wharton’s jelly), bone marrow, adipose tissue, peripheral blood, dermal and epithelial tissues, as well as fetal-derived cell populations where legally permitted. In addition, we utilize lineage-committed and tissue-specific cells such as neural progenitors, neurons, oligodendrocytes, astrocytes, chondrocytes, myoblasts, hepatocytes, endothelial and microvascular cells, allowing targeted interventions for neurological, musculoskeletal, cardiovascular, hepatic, and systemic disorders. This comprehensive cellular portfolio enables precise selection of biological products based on disease pathophysiology, stage, and individual patient characteristics.
A key component of our platform is the ability to cultivate and expand narrowly differentiated and induced cell populations under controlled laboratory conditions. Using advanced cell culture systems, we generate induced pluripotent stem cells (iPSC) from patient-derived somatic cells, followed by directed differentiation into specific neural, glial, mesenchymal, or epithelial lineages. This approach allows for personalized, genetically matched therapies with reduced immunological risk. In parallel, we apply genetic screening, quality control, and—where scientifically justified—targeted gene modulation or correction technologies to optimize cellular function, stability, and therapeutic potential. These processes are conducted in compliance with international biosafety, ethical, and regulatory standards, ensuring reproducibility and clinical reliability.
Beyond whole-cell therapies, our clinical and research programs actively incorporate intra- and extracellular biological products, recognizing their central role in regenerative signaling. This includes the therapeutic use of exosomes, extracellular vesicles, secretomes, growth factors, cytokines, microRNAs, mitochondrial fractions, and other intracellular derivatives that mediate paracrine and immunomodulatory effects. These acellular and subcellular components are used both as standalone biologic therapies and in combination with cellular transplantation to enhance tissue repair, modulate inflammation, promote angiogenesis, support neuroplasticity, and activate endogenous regeneration mechanisms. By integrating cell-based, gene-based, and cell-free regenerative strategies, our clinics cover all major directions of contemporary cell therapy, offering a scientifically grounded, multimodal approach to complex and chronic diseases. Find more information:Why Stem Cell Therapy Doesn’t Work for Some Patients ?
Austrian Laboratory in Graz: Advanced Bioengineering and Tissue Growth
In 2020, we expanded our international infrastructure by opening a specialized laboratory in Graz, Austria.
Focus of the Austrian Laboratory
This laboratory is dedicated to:
- Development of unique biologic products
- Advanced methods of genetic engineering
- Cultivation of specific tissue fragments
Tissue Engineering Projects
Research activities include:
- Skin regeneration constructs
- Joint cartilage fragments
- Liver tissue segments
These technologies aim to bridge the gap between cell therapy and functional tissue replacement.
Unique Bio Products and Genetic Engineering Approaches
The Austrian laboratory focuses on:
- Controlled gene expression modulation
- Enhancement of cell survival and integration
- Production of intracellular signaling compounds
- Development of exosome-based delivery systems
These innovations allow us to move beyond classical stem cell injections toward complex regenerative systems.
Individualized Treatment Philosophy
At the core of our clinical approach lies individualized regenerative therapy.
Comprehensive Medical Assessment
Each patient undergoes:
- Detailed medical history analysis
- Review of diagnostic imaging and laboratory data
- Functional and quality-of-life assessments
Personalized Protocol Design
Treatment protocols are designed based on:
- Disease stage and progression
- Patient age and biological reserve
- Comorbidities and risk factors
- Previous treatments and responses
No two protocols are identical.
Collegial Case Review and Ongoing Monitoring
All cases are reviewed by a multidisciplinary medical board, ensuring balanced decision-making.
One-Year Medical Supervision
After therapy, patients receive:
- Scheduled medical evaluations
- Laboratory and imaging follow-ups
- Continuous coordination with medical advisors
- Protocol adjustments if necessary
This long-term supervision maximizes therapeutic outcomes and patient safety.
Treatment Abroad: Patient Support and Logistics
We provide:
- International patient coordination
- Medical travel assistance
- Visa and documentation support
- Accommodation and local logistics
- Post-treatment remote monitoring
For patients unable to travel, home-based delivery of individualized cell programs is available only under medical supervision.
INTERESTING TO KNOW : Stem Cell Therapy – When to Expect Results
Long-Term Commitment to Results
Our mission extends beyond procedures. We focus on:
- Functional recovery
- Disease stabilization
- Quality-of-life improvement
- Long-term safety
This philosophy defines our role as a long-term medical partner, not just a treatment provider.
Conclusion: A Global Regenerative Medicine Ecosystem
Choosing stem cell treatment abroad requires trust, transparency, and scientific credibility. Our international clinic network offers a comprehensive regenerative ecosystem where clinical care, research, and innovation converge.
With official offices in Ukraine and Bulgaria, an advanced laboratory in Austria, access to all stem cell sources, and a strong research foundation, we provide patients with one of the most advanced and individualized regenerative medicine solutions available today.
CONTACT FOR FREE
MEDICAL CONSULTATION
